S&P 500   3,872.71 (+0.80%)
DOW   32,117.35 (+1.97%)
QQQ   306.44 (-0.73%)
AAPL   118.12 (-2.72%)
MSFT   231.18 (-0.18%)
FB   260.44 (-1.45%)
GOOGL   2,064.77 (-1.54%)
TSLA   585.06 (-2.16%)
AMZN   3,006.71 (+0.21%)
NVDA   476.08 (-4.49%)
BABA   229.02 (-2.08%)
CGC   31.61 (+1.41%)
GE   14.29 (+5.07%)
MU   87.15 (-2.00%)
NIO   37.01 (-2.89%)
AMD   76.25 (-2.89%)
T   30.34 (+2.43%)
F   12.82 (+4.48%)
ACB   9.83 (+2.40%)
DIS   201.33 (+5.97%)
BA   228.27 (+2.26%)
NFLX   509.57 (-1.32%)
PFE   34.85 (+1.34%)
S&P 500   3,872.71 (+0.80%)
DOW   32,117.35 (+1.97%)
QQQ   306.44 (-0.73%)
AAPL   118.12 (-2.72%)
MSFT   231.18 (-0.18%)
FB   260.44 (-1.45%)
GOOGL   2,064.77 (-1.54%)
TSLA   585.06 (-2.16%)
AMZN   3,006.71 (+0.21%)
NVDA   476.08 (-4.49%)
BABA   229.02 (-2.08%)
CGC   31.61 (+1.41%)
GE   14.29 (+5.07%)
MU   87.15 (-2.00%)
NIO   37.01 (-2.89%)
AMD   76.25 (-2.89%)
T   30.34 (+2.43%)
F   12.82 (+4.48%)
ACB   9.83 (+2.40%)
DIS   201.33 (+5.97%)
BA   228.27 (+2.26%)
NFLX   509.57 (-1.32%)
PFE   34.85 (+1.34%)
S&P 500   3,872.71 (+0.80%)
DOW   32,117.35 (+1.97%)
QQQ   306.44 (-0.73%)
AAPL   118.12 (-2.72%)
MSFT   231.18 (-0.18%)
FB   260.44 (-1.45%)
GOOGL   2,064.77 (-1.54%)
TSLA   585.06 (-2.16%)
AMZN   3,006.71 (+0.21%)
NVDA   476.08 (-4.49%)
BABA   229.02 (-2.08%)
CGC   31.61 (+1.41%)
GE   14.29 (+5.07%)
MU   87.15 (-2.00%)
NIO   37.01 (-2.89%)
AMD   76.25 (-2.89%)
T   30.34 (+2.43%)
F   12.82 (+4.48%)
ACB   9.83 (+2.40%)
DIS   201.33 (+5.97%)
BA   228.27 (+2.26%)
NFLX   509.57 (-1.32%)
PFE   34.85 (+1.34%)
S&P 500   3,872.71 (+0.80%)
DOW   32,117.35 (+1.97%)
QQQ   306.44 (-0.73%)
AAPL   118.12 (-2.72%)
MSFT   231.18 (-0.18%)
FB   260.44 (-1.45%)
GOOGL   2,064.77 (-1.54%)
TSLA   585.06 (-2.16%)
AMZN   3,006.71 (+0.21%)
NVDA   476.08 (-4.49%)
BABA   229.02 (-2.08%)
CGC   31.61 (+1.41%)
GE   14.29 (+5.07%)
MU   87.15 (-2.00%)
NIO   37.01 (-2.89%)
AMD   76.25 (-2.89%)
T   30.34 (+2.43%)
F   12.82 (+4.48%)
ACB   9.83 (+2.40%)
DIS   201.33 (+5.97%)
BA   228.27 (+2.26%)
NFLX   509.57 (-1.32%)
PFE   34.85 (+1.34%)
Log in
NASDAQ:AERI

Aerie Pharmaceuticals Stock Forecast, Price & News

$19.66
+0.91 (+4.85 %)
(As of 03/8/2021 01:15 PM ET)
Add
Compare
Today's Range
$18.65
Now: $19.66
$19.89
50-Day Range
$13.95
MA: $16.83
$19.80
52-Week Range
$9.01
Now: $19.66
$20.46
Volume6,774 shs
Average Volume807,749 shs
Market Capitalization$922.39 million
P/E RatioN/A
Dividend YieldN/A
Beta0.79
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Aerie Pharmaceuticals logo

Headlines

Is AERI A Good Stock To Buy Now?
December 17, 2020 |  finance.yahoo.com
Why Is Aerie (AERI) Up 19% Since Last Earnings Report?
December 5, 2020 |  finance.yahoo.com
Aerie Pharmaceuticals
November 27, 2020 |  fool.com
European advisory group backs Aerie Pharma's Roclanda
November 13, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300
Employees380
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$69.89 million
Book Value$3.60 per share

Profitability

Net Income$-199,580,000.00
Net Margins-231.05%

Miscellaneous

Market Cap$922.39 million
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.73 out of 5 stars

Medical Sector

207th out of 1,968 stocks

Biological Products, Except Diagnostic Industry

26th out of 177 stocks

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$19.66
+0.91 (+4.85 %)
(As of 03/8/2021 01:15 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

Is Aerie Pharmaceuticals a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aerie Pharmaceuticals stock.
View analyst ratings for Aerie Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Aerie Pharmaceuticals?

Wall Street analysts have given Aerie Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aerie Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Aerie Pharmaceuticals
.

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its earnings results on Thursday, February, 25th. The company reported ($0.79) EPS for the quarter, missing the Zacks' consensus estimate of ($0.75) by $0.04. Aerie Pharmaceuticals had a negative net margin of 231.05% and a negative trailing twelve-month return on equity of 135.57%.
View Aerie Pharmaceuticals' earnings history
.

How has Aerie Pharmaceuticals' stock been impacted by Coronavirus?

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AERI stock has increased by 35.1% and is now trading at $19.66.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AERI?

11 brokerages have issued 1-year price objectives for Aerie Pharmaceuticals' shares. Their forecasts range from $9.00 to $40.00. On average, they anticipate Aerie Pharmaceuticals' stock price to reach $25.50 in the next twelve months. This suggests a possible upside of 29.7% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the following people:
  • Dr. Vicente J. Anido Jr., CEO & Chairman (Age 68, Pay $1.13M)
  • Mr. Thomas A. Mitro, Pres & COO (Age 63, Pay $582.78k)
  • Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 60, Pay $582.51k)
  • Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 63, Pay $620.37k)
  • Mr. John W. LaRocca Esq., Gen. Counsel & Assistant Sec. (Age 55, Pay $576.3k)
  • Mr. Jeffrey Calabrese, Director of Accounting
  • Ms. Ami Bavishi, Director of Investor Relations
  • Andrew Allen, Chief Compliance Officer
  • Mr. Tad Heitmann, Head of Communications
  • Evan Hockman, VP of Sales

Who are some of Aerie Pharmaceuticals' key competitors?

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include William Blair Investment Management LLC (3.23%), Schroder Investment Management Group (3.00%), Rice Hall James & Associates LLC (2.92%), Citigroup Inc. (2.67%), Pinnacle Associates Ltd. (1.59%) and Clearbridge Investments LLC (1.37%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino and Vicente Anido Jr.
View institutional ownership trends for Aerie Pharmaceuticals
.

Which major investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Stifel Financial Corp, Frontier Capital Management Co. LLC, Voloridge Investment Management LLC, Barclays PLC, Rice Hall James & Associates LLC, Renaissance Technologies LLC, and Candriam Luxembourg S.C.A.. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Casey C Kopczynski, and Gerald D Cagle.
View insider buying and selling activity for Aerie Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Aerie Pharmaceuticals stock?

AERI stock was acquired by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Norges Bank, Pinnacle Associates Ltd., DNB Asset Management AS, Endurance Wealth Management Inc., William Blair Investment Management LLC, State of Wisconsin Investment Board, and Morgens Waterfall Vintiadis & Co. Inc.. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Richard J Rubino, and Vicente Anido Jr.
View insider buying and selling activity for Aerie Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $19.66.

How much money does Aerie Pharmaceuticals make?

Aerie Pharmaceuticals has a market capitalization of $922.39 million and generates $69.89 million in revenue each year. The company earns $-199,580,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis.

How many employees does Aerie Pharmaceuticals have?

Aerie Pharmaceuticals employs 380 workers across the globe.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

Where are Aerie Pharmaceuticals' headquarters?

Aerie Pharmaceuticals is headquartered at 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.